DE60134009D1 - Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose - Google Patents

Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose

Info

Publication number
DE60134009D1
DE60134009D1 DE60134009T DE60134009T DE60134009D1 DE 60134009 D1 DE60134009 D1 DE 60134009D1 DE 60134009 T DE60134009 T DE 60134009T DE 60134009 T DE60134009 T DE 60134009T DE 60134009 D1 DE60134009 D1 DE 60134009D1
Authority
DE
Germany
Prior art keywords
atherosclerosis
inhibitors
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60134009T
Other languages
English (en)
Inventor
Yolande Chvatchko
Alain Tedgui
Ziad Mallat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Laboratoires Serono SA
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono SA, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Laboratoires Serono SA
Application granted granted Critical
Publication of DE60134009D1 publication Critical patent/DE60134009D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE60134009T 2000-05-05 2001-04-30 Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose Expired - Lifetime DE60134009D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00109606 2000-05-05
PCT/EP2001/004843 WO2001085201A2 (en) 2000-05-05 2001-04-30 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis

Publications (1)

Publication Number Publication Date
DE60134009D1 true DE60134009D1 (de) 2008-06-26

Family

ID=8168631

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60134009T Expired - Lifetime DE60134009D1 (de) 2000-05-05 2001-04-30 Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose

Country Status (33)

Country Link
US (1) US20040076628A1 (de)
EP (1) EP1278540B1 (de)
JP (1) JP5122053B2 (de)
KR (2) KR100798545B1 (de)
CN (2) CN1250286C (de)
AR (1) AR035640A1 (de)
AT (1) ATE395075T1 (de)
AU (2) AU6739001A (de)
BG (1) BG65881B1 (de)
BR (1) BRPI0110506B8 (de)
CA (1) CA2407895C (de)
CY (1) CY1110385T1 (de)
CZ (1) CZ300792B6 (de)
DE (1) DE60134009D1 (de)
DK (1) DK1278540T3 (de)
EA (2) EA007014B1 (de)
EE (1) EE05056B1 (de)
ES (1) ES2305082T3 (de)
HK (2) HK1055681A1 (de)
HR (1) HRP20020828A2 (de)
HU (1) HU229375B1 (de)
IL (2) IL152567A0 (de)
ME (1) ME00554B (de)
MX (1) MXPA02010895A (de)
NO (1) NO329821B1 (de)
PL (1) PL209371B1 (de)
PT (1) PT1278540E (de)
RS (1) RS50926B (de)
SI (1) SI1278540T1 (de)
SK (1) SK287761B6 (de)
UA (2) UA87658C2 (de)
WO (1) WO2001085201A2 (de)
ZA (1) ZA200208228B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
CA2435466C (en) * 2001-01-29 2012-04-03 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of heart disease
CA2445664C (en) * 2001-05-25 2012-03-06 Ares Trading S.A. Use of il-18 inhibitors for treating or preventing cns injuries
US6797727B2 (en) 2001-07-16 2004-09-28 Transition Therapeutics Inc. Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
PT1487541E (pt) * 2002-03-22 2008-12-10 Inst Nat Sante Rech Med Utilização de inibidores de il-8 para o tratamento e/ou prevenção de doenças vasculares periféricas
ATE399872T1 (de) * 2003-03-11 2008-07-15 Serono Lab Expressionvektoren, die den promotor des ie2-gens des maus cytomegalovirus enthalten
EP1622939B1 (de) 2003-05-13 2012-03-14 Merck Serono SA Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US20080044404A1 (en) * 2004-04-15 2008-02-21 Anna Cederholm Annexin V for Preventing Atherothrombosis and Plaque Rupture
CN101219208B (zh) * 2005-01-04 2010-08-11 健能隆医药技术（上海）有限公司 白介素-22的医药用途
PT1885753E (pt) 2005-06-03 2011-10-06 Ares Trading Sa Produção de proteína recombinante de ligação a il-18
WO2006131550A1 (en) 2005-06-10 2006-12-14 Ares Trading S.A. Process for the purification of il-18 binding protein
AR082518A1 (es) 2010-08-25 2012-12-12 Hoffmann La Roche Anticuerpos contra il-18r1 y usos de los mismos
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
MD707Z (ro) * 2013-01-18 2014-07-31 Институт Зоологии Академии Наук Молдовы Metodă de identificare a secvenţelor polimorfe 4a/4b ale genei sintetazei endoteliale a oxidului nitric
SG11201601717VA (en) 2013-09-05 2016-04-28 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
CN107660150B (zh) 2015-03-05 2023-10-24 Ab2生物股份有限公司 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
CN110273591B (zh) 2019-08-13 2023-12-12 上海杉脉电子科技发展有限公司 一种单动力微型智能锁
TW202233675A (zh) 2020-10-29 2022-09-01 瑞士商諾華公司 Ｉｌ－１８拮抗劑用於治療和／或預防異位性皮炎或相關病症之用途
CN112972655A (zh) * 2021-04-16 2021-06-18 武汉大学 白细胞介素12在制备预防、缓解和/或治疗主动脉瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP0987552A3 (de) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulphonylharnstoff-Bindungsproteine
WO2000012555A1 (fr) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Proteine de liaison de l'interleukine 18

Also Published As

Publication number Publication date
BRPI0110506B1 (pt) 2015-05-19
EE200200620A (et) 2004-06-15
MXPA02010895A (es) 2003-03-27
UA87658C2 (uk) 2009-08-10
CZ300792B6 (cs) 2009-08-12
EA007014B1 (ru) 2006-06-30
HUP0301991A3 (en) 2006-11-28
NO20025307L (no) 2002-12-18
EA005410B1 (ru) 2005-02-24
MEP64008A (en) 2011-12-20
SI1278540T1 (sl) 2008-10-31
CZ20023644A3 (cs) 2003-03-12
CN1841066B (zh) 2012-08-29
JP2003532685A (ja) 2003-11-05
DK1278540T3 (da) 2008-07-21
HUP0301991A2 (hu) 2003-09-29
KR20030016254A (ko) 2003-02-26
ZA200208228B (en) 2005-07-27
BRPI0110506B8 (pt) 2021-05-25
HK1055681A1 (en) 2004-01-21
AR035640A1 (es) 2004-06-23
CN1250286C (zh) 2006-04-12
EE05056B1 (et) 2008-08-15
CA2407895A1 (en) 2001-11-15
HU229375B1 (en) 2013-11-28
ATE395075T1 (de) 2008-05-15
ES2305082T3 (es) 2008-11-01
IL152567A (en) 2010-12-30
KR100798545B1 (ko) 2008-01-28
PT1278540E (pt) 2008-07-03
SK287761B6 (en) 2011-09-05
UA78492C2 (en) 2007-04-10
JP5122053B2 (ja) 2013-01-16
AU2001267390B2 (en) 2005-09-22
US20040076628A1 (en) 2004-04-22
NO20025307D0 (no) 2002-11-05
SK15562002A3 (sk) 2003-05-02
PL209371B1 (pl) 2011-08-31
EA200401183A1 (ru) 2004-12-30
BG107218A (bg) 2003-06-30
EA200201175A1 (ru) 2003-04-24
CN1841066A (zh) 2006-10-04
IL152567A0 (en) 2003-05-29
YU82602A (sh) 2006-01-16
RS50926B (sr) 2010-08-31
CA2407895C (en) 2012-12-18
CY1110385T1 (el) 2015-04-29
BG65881B1 (bg) 2010-04-30
PL365697A1 (en) 2005-01-10
NO329821B1 (no) 2010-12-27
BR0110506A (pt) 2003-04-01
CN1434722A (zh) 2003-08-06
HK1094909A1 (en) 2007-04-13
WO2001085201A2 (en) 2001-11-15
AU6739001A (en) 2001-11-20
EP1278540A2 (de) 2003-01-29
HRP20020828A2 (en) 2004-12-31
EP1278540B1 (de) 2008-05-14
WO2001085201A3 (en) 2002-05-10
ME00554B (me) 2012-03-20
KR20070073989A (ko) 2007-07-10

Similar Documents

Publication Publication Date Title
DE60134009D1 (de) Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE60324777D1 (de) Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten
DE60142590D1 (de) Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen
DE60221627D1 (de) Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
DE60035378D1 (de) Gerät zur Behandlung von Bandscheiben
ATE323661T1 (de) Behandlung von mineralischen stoffen
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE50212701D1 (de) Bestrahlungsanordnung zur behandlung von akne und aknenarben
DE60214542D1 (de) Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks
DE60221798D1 (de) Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
ATE376444T1 (de) Ibandronsäure zur behandlung und vorbeugung von osteoporose
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE366569T1 (de) Verwendung von cox-2 inhibitoren als immunostimulantien zur behandlung von hiv oder aids
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
DE50111926D1 (de) Strahlungsanordnung sowie deren Verwendung und Verfahren zur Behandlung von Oberflächen
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60305400D1 (de) Anlage zur Behandlung von Produkten und dazugehörige Datenerfassungseinheit
DE60125212D1 (de) Verwendung von Aivlosin zur Behandlung und Prevention der Lawsonia-Infektionen in Schweinen.
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
DE60317655D1 (de) Behandlung zur verwertung von abfallverbrennungsrückständen und dergleichen
DE69715878D1 (de) Formulierung zur behandlung und/oder vorbeugung von dementia
AR028025A1 (es) Metodo e indicador de tratamiento de mosquiteros
DE59904564D1 (de) Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien

Legal Events

Date Code Title Description
8364 No opposition during term of opposition